Viridian Therapeutics Inc

VRDN · NASDAQ

Medical Laboratories

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.

ESG Scores

Overall ESG

6.8

Environmental

7.3

Social

3.6

Governance

6.1

Gender Diversity

Female Directors0.4%

CEO GenderMale

Market Data

Price$16.57+0.22 (+1.35%)

Market Cap$1.81B

P/E Ratio—

EPS$—

52W High$34.29

52W Low$13.18

Beta0.92